Showing results (81-90 of 151) with videos related to

Sort By:
Pageof 16
Inflammatory Bowel Diseases|August 13, 2011
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitisSunanda Kane, Seymour Katz, M Mazen Jamal, et al.
Digestive Diseases and Sciences|October 21, 2017
Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel DiseaseAlexis Calloway, Robin Dalal, Dawn B Beaulieu, et al.
Inflammatory Bowel Diseases|April 15, 2017
Sarcopenia Is Common in Overweight Patients with Inflammatory Bowel Disease and May Predict Need for SurgeryDawn W Adams, Shelly Gurwara, Heidi J Silver, et al.
Biomedical Optics Express|March 9, 2017
Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopyIsaac J Pence, Dawn B Beaulieu, Sara N Horst, et al.
Crohn'S & Colitis 360|August 4, 2020
Gastroenterologist-Lead Management of Iron Deficiency Anemia in Inflammatory Bowel Disease Is Effective, Safe, and May Increase Quality of LifeChristopher L Coe, Matthew H Meyers, Dawn B Beaulieu, et al.
Annals of Gastroenterology|January 3, 2017
Effects of caregiver burden on quality of life and coping strategies utilized by caregivers of adult patients with inflammatory bowel diseaseNimisha K Parekh, Shamita Shah, Kristin McMaster, et al.
The American Journal of Gastroenterology|July 23, 2025
ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel DiseaseFrancis A Farraye, Gil Y Melmed, Gary R Lichtenstein, et al.
Clinical and Translational Gastroenterology|March 18, 2025
Healthcare Providers' Perspectives on Anoreceptive Intercourse in Sexual and Gender Minorities With Ileal Pouch Anal AnastomosisDarine Daher, Kira L Newman, Rachel Canning, et al.
The Cochrane Database of Systematic Reviews|November 28, 2018
Fecal transplantation for treatment of inflammatory bowel diseaseAamer Imdad, Maribeth R Nicholson, Emily E Tanner-Smith, et al.
Journal of Medical Economics|May 12, 2025
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspectiveAnkit Gulati, Neha Mittal, Sunanda Kane, et al.
Pageof 16